MedTrace Logo

Safety and Efficacy of Exosomes Overexpressing CD24 in Two Doses for Patients With Moderate or Severe COVID-19

NCT04902183 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 90

Last updated 2021-06-15

No results posted yet for this study

Summary

This is a phase II randomized, single-blind dose study to evaluate the safety and efficacy of exosomes overexpressing CD24 of two doses, Dose 1 - 10\^9 exosome particles (per dose) versus Dose 2 - 10\^10 exosome particles (per dose), to prevent clinical deterioration in patients with Moderate or Severe COVID-19 infection.

Conditions

  • Covid19

Interventions

DRUG

CovenD24

The drug will be administrated once daily for 5 days

Sponsors & Collaborators

  • OBCTCD24 Ltd

    collaborator UNKNOWN

  • Elpen Pharmaceutical Co. Inc.

    collaborator INDUSTRY

  • Athens Medical Society

    lead OTHER

Principal Investigators

  • Sotirios Tsiodras, Prof · Attikon University Hospital, Athens, Greece

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-06-09
Primary Completion
2021-09-01
Completion
2021-09-01

Countries

  • Greece

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04902183 on ClinicalTrials.gov